Adjuvant chemoradiotherapy

Adjuvant chemoradiotherapy

The landmark RTOG 9501 and EORTC 22931 randomised - trials form the basis for the contemporary role of adjuvant chemotherapy (CRT) in high-risk OCSCC (although only 25% benefit conferred by adding high-dose cisplatin to conventional postoperative radiotherapy (RT), with primary end points of locoregional control and progression-free survival, respectively . Positive surgical margins and extracapsular extension (ECE; now ENE) were used to classify patients as high risk in both studies, while several other criteria unique to each were also investigated. Ultimately , and following several associated long term, subgroup and pooled analyses, these trials provided strong evidence for the use of concurrent cisplatin-based CRT in high-risk patients. Adjuvant chemoradiotherapy

The landmark RTOG 9501 and EORTC 22931 randomised - trials form the basis for the contemporary role of adjuvant chemotherapy (CRT) in high-risk OCSCC (although only 25% benefit conferred by adding high-dose cisplatin to conventional postoperative radiotherapy (RT), with primary end points of locoregional control and progression-free survival, respectively . Positive surgical margins and extracapsular extension (ECE; now ENE) were used to classify patients as high risk in both studies, while several other criteria unique to each were also investigated. Ultimately , and following several associated long term, subgroup and pooled analyses, these trials provided strong evidence for the use of concurrent cisplatin-based CRT in high-risk patients.